Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 4
2012 1
2013 2
2014 1
2015 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States.
Wakatsuki T, LaBonte MJ, Bohanes PO, Zhang W, Yang D, Azuma M, Barzi A, Ning Y, Loupakis F, Saadat S, Volz N, Stintzing S, El-Khoueiry R, Koizumi W, Watanabe M, Shah M, Stebbing J, Giamas G, Lenz HJ. Wakatsuki T, et al. Mol Cancer Ther. 2013 Oct;12(10):2261-72. doi: 10.1158/1535-7163.MCT-12-1134. Epub 2013 Aug 5. Mol Cancer Ther. 2013. PMID: 23918832 Free PMC article.
Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
Gerger A, El-Khoueiry A, Zhang W, Yang D, Singh H, Bohanes P, Ning Y, Winder T, Labonte MJ, Wilson PM, Benhaim L, Paez D, El-Khoueiry R, Absenger G, Lenz HJ. Gerger A, et al. Clin Cancer Res. 2011 Sep 1;17(17):5783-92. doi: 10.1158/1078-0432.CCR-11-1115. Epub 2011 Jul 26. Clin Cancer Res. 2011. PMID: 21791631 Free PMC article.
EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients.
Hu-Lieskovan S, Vallbohmer D, Zhang W, Yang D, Pohl A, Labonte MJ, Grimminger PP, Hölscher AH, Semrau R, Arnold D, Dellas K, Debucquoy A, Haustermans K, Machiels JP, Sempoux C, Rödel C, Bracko M, Velenik V, Lenz HJ. Hu-Lieskovan S, et al. Clin Cancer Res. 2011 Aug 1;17(15):5161-9. doi: 10.1158/1078-0432.CCR-10-2666. Epub 2011 Jun 14. Clin Cancer Res. 2011. PMID: 21673069 Free PMC article.
Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy.
Pohl A, El-Khoueiry A, Yang D, Zhang W, Lurje G, Ning Y, Winder T, Hu-Lieskoven S, Iqbal S, Danenberg KD, Kahn M, Teo JL, Shriki J, Stebbing J, Lenz HJ. Pohl A, et al. Pharmacogenomics J. 2013 Apr;13(2):173-80. doi: 10.1038/tpj.2011.61. Epub 2012 Jan 10. Pharmacogenomics J. 2013. PMID: 22231565 Free PMC article.